|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0706 EUR | -3.95% |
|
+2.32% | +8.28% |
| Jan. 05 | TME Pharma N.V. Provides Update on Its Activities | CI |
| Nov. 17 | TME Pharma N.V. Announces Extension of Certain Bond Agreements | CI |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | - | |||||
Other Revenues, Total | 35K | 33K | - | - | - | |||||
Total Revenues | 35K | 33K | - | - | - | |||||
Cost of Goods Sold, Total | - | - | - | - | - | |||||
Gross Profit | 35K | 33K | - | - | - | |||||
Selling General & Admin Expenses, Total | 1.88M | 2.88M | 3.88M | 2.99M | 2.98M | |||||
R&D Expenses | 4.02M | 10.66M | 8.15M | 2.65M | 2.3M | |||||
Other Operating Expenses | -39K | -39K | -16K | -17K | -19K | |||||
Other Operating Expenses, Total | 5.86M | 13.49M | 12.01M | 5.62M | 5.26M | |||||
Operating Income | -5.82M | -13.46M | -12.01M | -5.62M | -5.26M | |||||
Interest Expense, Total | -3K | -49K | -133K | -17K | -18K | |||||
Interest And Investment Income | - | - | - | - | - | |||||
Net Interest Expenses | -3K | -49K | -133K | -17K | -18K | |||||
Currency Exchange Gains (Loss) | 12K | 184K | -33K | 9K | 7K | |||||
Other Non Operating Income (Expenses) | -5.04M | -1.42M | -3.27M | -1.34M | -453K | |||||
EBT, Excl. Unusual Items | -10.86M | -14.74M | -15.45M | -6.97M | -5.72M | |||||
Restructuring Charges | - | - | - | - | - | |||||
Asset Writedown | - | - | - | - | - | |||||
Other Unusual Items | 449K | 291K | 321K | 237K | - | |||||
EBT, Incl. Unusual Items | -10.41M | -14.45M | -15.13M | -6.73M | -5.72M | |||||
Income Tax Expense | - | 1K | 7K | 2K | - | |||||
Earnings From Continuing Operations | -10.41M | -14.45M | -15.13M | -6.74M | -5.72M | |||||
Net Income to Company | -10.41M | -14.45M | -15.13M | -6.74M | -5.72M | |||||
Minority Interest | 1K | 1K | 1K | - | - | |||||
Net Income - (IS) | -10.4M | -14.45M | -15.13M | -6.74M | -5.72M | |||||
Net Income to Common Incl Extra Items | -10.4M | -14.45M | -15.13M | -6.74M | -5.72M | |||||
Net Income to Common Excl. Extra Items | -10.4M | -14.45M | -15.13M | -6.74M | -5.72M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -32.16 | -21.9 | -12.86 | -1.34 | -0.16 | |||||
Basic EPS - Continuing Operations | -32.16 | -21.9 | -12.86 | -1.34 | -0.16 | |||||
Basic Weighted Average Shares Outstanding | 324K | 660K | 1.18M | 5.02M | 35.98M | |||||
Net EPS - Diluted | -32.16 | -21.9 | -12.86 | -1.34 | -0.16 | |||||
Diluted EPS - Continuing Operations | -32.16 | -21.9 | -12.86 | -1.34 | -0.16 | |||||
Diluted Weighted Average Shares Outstanding | 324K | 660K | 1.18M | 5.02M | 35.98M | |||||
Normalized Basic EPS | -20.96 | -13.96 | -8.21 | -0.87 | -0.1 | |||||
Normalized Diluted EPS | -20.96 | -13.96 | -8.21 | -0.87 | -0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | -5.81M | -13.44M | -11.99M | -5.59M | -5.24M | |||||
EBITA | -5.82M | -13.46M | -12.01M | -5.62M | -5.26M | |||||
EBIT | -5.82M | -13.46M | -12.01M | -5.62M | -5.26M | |||||
EBITDAR | -5.8M | -13.44M | -11.99M | -5.59M | - | |||||
Effective Tax Rate - (Ratio) | - | -0.01 | -0.05 | -0.03 | - | |||||
Current Domestic Taxes | - | 1K | 7K | 2K | - | |||||
Total Current Taxes | - | 1K | 7K | 2K | - | |||||
Deferred Domestic Taxes | - | - | - | - | - | |||||
Total Deferred Taxes | - | - | - | - | - | |||||
Normalized Net Income | -6.78M | -9.21M | -9.65M | -4.36M | -3.58M | |||||
Interest on Long-Term Debt | 126K | 49K | 133K | 17K | 18K | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 1.88M | 2.88M | 3.88M | 2.99M | 2.98M | |||||
Research And Development Expense From Footnotes | 4.02M | 10.66M | 8.15M | 2.65M | 2.3M | |||||
Net Rental Expense, Total | 2K | 2K | 3K | 6K | - | |||||
Imputed Operating Lease Interest Expense | 407 | 507 | 978 | 311 | - | |||||
Imputed Operating Lease Depreciation | 1.59K | 1.49K | 2.02K | 5.69K | - | |||||
Maintenance & Repair Expenses, Total | - | - | - | - | - | |||||
Stock-Based Comp., R&D Exp. (Total) | 51K | 166K | 201K | 123K | 86K | |||||
Stock-Based Comp., G&A Exp. (Total) | 111K | 309K | 388K | 273K | 226K | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 162K | 475K | 589K | 396K | 312K |
- Stock Market
- Equities
- ALTME Stock
- Financials TME Pharma N.V.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















